Skip to main content

Recurrent Genital Herpes Simplex Type 2

2
Pipeline Programs
1
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Assembly Biosciences
Assembly BiosciencesSOUTH SAN FRANCISCO, CA
2 programs
2
ABI-1179Phase 11 trial
ABI-5366Phase 11 trial
Active Trials
NCT06698575Completed103Est. Jan 2026
NCT06385327Completed115Est. Feb 2026

Trial Timeline

Clinical trial activity over time

2024
2025
2026
Assembly BiosciencesABI-1179
Assembly BiosciencesABI-5366

Clinical Trials (2)

Total enrollment: 218 patients across 2 trials

A Study to Assess the Safety, Pharmacokinetics, and Tolerability of ABI-1179 in Healthy Subjects and in Subjects Seropositive for HSV-2 With Recurrent Genital Herpes

Start: Dec 2024Est. completion: Jan 2026103 patients
Phase 1Completed

A Study to Assess the Safety, Pharmacokinetics, and Antiviral Activity of ABI-5366 in Healthy Participants and Participants Seropositive for HSV-2 With Recurrent Genital Herpes

Start: May 2024Est. completion: Feb 2026115 patients
Phase 1Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.